首页 | 本学科首页   官方微博 | 高级检索  
检索        


Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype
Institution:1. Department of Surgery (Otolaryngology);2. Department of Internal Medicine (Medical Oncology);3. Department of Pathology, Yale University School of Medicine, New Haven, USA;4. Department of Cranio-, Maxillofacial and Oral Surgery, Medical University of Vienna, Vienna, Austria;5. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA;6. Department of Pathology;7. Department of Medical Oncology, Papageorgiou Hospital Aristotle University of Thessaloniki, Thessaloniki;8. Department of Medicine, National Kapodistrian University of Athens, Attikon Hospital, Athens, Greece
Abstract:BackgroundWe sought to determine biomarker expression differences in head and neck squamous cell cancers (HNSCCs) based on p16/human papillomavirus (HPV) classification. In addition, our aim was to explore how expression of biomarkers is modulated after E6/E7 repression in HPV16+ oropharyngeal cancer cells.MethodsHPV16+ and HPV- HNSCC cells were infected with retroviruses expressing short hairpin RNA targeting HPV16 E6/E7. Components of the epidermal growth factor receptor (EGFR) pathway before and after E6/E7 gene silencing were analyzed by immunoblotting and qRT–PCR. Protein expression of 13 biomarkers was analyzed using AQUA on a tissue microarray (TMA). The HPV16 status was determined using HPV16 in situ hybridization (ISH).ResultsIn HPV16+ cells, E6/E7 silencing was associated with PTEN upregulation and reduction of phosphorylated EGFR. Tumors were classified into four categories based on the HPV and p16 status. HPV+/p16+ tumors expressed significantly higher levels of E-cadherin (P = 0.003), PTEN (P = 0.004), lower levels of PI3Kp110 and β-catenin (P = 0.07). There was a significant difference in overall survival (OS, P = 0.016) among the four subsets. The median OS was 24.83 months for p16-/HPV- patients, 11.63 for p16-/HPV+ patients and was not reached for p16+/HPV- and p16+/HPV+ groups.ConclusionsAberrant EGFR signaling contributes to malignant conversion of HPV16+ HNSCC cells. These results validate β-catenin as a distinct biomarker in HPV+/p16+ HNSCC. Wnt signaling inhibitors merit exploration in HPV+/p16+ HNSCC.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号